Genentech, Affimed Launch Up-to-$5B Cancer Immunotherapy Collaboration

Genentech, a member of the Roche Group, has committed up to $5 billion in potential milestone payments and royalties to Affimed under a collaboration designed to develop and commercialize novel NK cell engager-based immunotherapies to treat multiple cancers.The collaboration, announced yesterday, will become the third-most valuable immuno-oncology partnership based on GEN’s list of Top 10 Immuno-Oncology Collaborations , last updated March 26.Genentech will use Affimed’s proprietary